Intermountain Health has announced the launch of Culmination Bio, a biotech company that will develop an anonymized and de-identified intelligence platform for healthcare data. Intermountain, a not-for-profit organization that operates a network of 33 hospitals and a medical group with over 59,000 caregivers in the western United States, said the new platform will create value for patients by developing novel clinical insights, discoveries and care processes.
Culmination’s multi-modal intelligence platform will{mprestriction ids="1,3"} provide its customers with access to omics-level data and a powerful insights engine for medical research, health data and healthcare services. Real-world data and evidence generation tied to the performance of diagnostics and therapeutics is a core component of the Culmination intelligence database, the company said.
“Culmination Bio was built to expand on the success of Intermountain’s precision medicine efforts by creating longitudinal multi-modal data sets. Culmination’s powerful insights platform will unlock the next generation of discoveries to advance healthcare,” said Dr. Lincoln Nadauld, who has been appointed CEO of Culmination Bio. “Our focus is to discover better health for patients everywhere. Our partnership with Intermountain Health has enabled us to build a platform that will revolutionize the way we identify and implement novel clinical insights to benefit patients.”
“We are thrilled to announce our partnership with Culmination Bio and the launch of its cutting-edge clinical discovery platform,” said Nickolas Mark, of Intermountain Ventures, the investment arm of Intermountain Health. “This technology will revolutionize the way clinicians and researchers identify diseases and corresponding treatments. It has been a pleasure working with the Culmination team to build out a platform that will improve patient outcomes across the board.”
In addition to Nadauld, other officers of Culmination Bio include Michael Wiley, chief operating officer; Mark Oldroyd, chief commercial officer; McCall Rowley, interim chief financial officer; Casey Frankenberger, senior vice president and head of data; David Jones, senior vice president and head of science; and Harry Hayter, senior vice president of strategic partnerships.
The Culmination Intelligence Platform includes millions of data points and represents a robust environment for sophisticated queries of data to identify new diagnostic tests and treatments that will result in better care for patients, Nadauld said. Commercial partners, including technology and biopharmaceutical companies, and healthcare institutions, along with the millions of patients treated by these organizations, will partner with Culmination in an effort to make novel medical discoveries and advances in precision medicine.{/mprestriction}
